Current and emerging drug targets in heart failure treatment
Heart Failure Reviews · 2022-07 · 27 (4) · 1119-1136
DOI: 10.1007/s10741-021-10137-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Heart Failure Reviews, online erschienen am 17.07.2021. Verfasst von Nicolò Ghionzoli und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Heart Failure, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scuola Superiore Sant'Anna.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
After initial strategies targeting inotropism and congestion, the neurohormonal interpretative model of heart failure (HF) pathophysiology has set the basis for current pharmacological management of HF, as most of guideline recommended drug classes, including beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and mineralocorticoid receptor antagonists, blunt the activation of detrimental neurohormonal axes, namely sympathetic and renin–angiotensin–aldosterone (RAAS) systems. More recently, sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor, combining inhibition of RAAS and potentiation of the counter-regulatory natriuretic peptide system, has been consistently demonstrated to reduce mortality and HF-related hospitalization. A number of novel pharmacological approaches have been tested during the latest years, leading to mixed results. Among them, drugs acting directly at a second messenger level, such as the soluble guanylate cyclase stimulator vericiguat, or other addressing myocardial energetics and mitochondrial function, such as elamipretide or omecamtiv-mecarbil, will likely change the therapeutic management of patients with HF. Sodium glucose cotransporter 2 inhibitors, initially designed for the management of type 2 diabetes mellitus, have been recently demonstrated to improve outcome in HF, although mechanisms of their action on cardiovascular system are yet to be elucidated. Most of these emerging approaches have shifted the therapeutic target from neurohormonal systems to the heart, by improving cardiac contractility, metabolism, fibrosis, inflammation, and remodeling. In the present paper, we review from a pathophysiological perspective current and novel therapeutic strategies in chronic HF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy.
- Cardiology Division, University Hospital of Pisa, Pisa, Italy.
- Division of Cardiology and Cardiovascular Medicine, Fondazione Toscana Gabriele Monasterio, Via Moruzzi, 1 - 56124, Pisa, Italy.
- Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.
- Fondazione Toscana Gabriele Monasterio, Pisa, Italy.
- Division of Cardiology and Cardiovascular Medicine, Fondazione Toscana Gabriele Monasterio, Via Moruzzi, 1 - 56124, Pisa, Italy. vergaro@ftgm.it.
Förderung
- Scuola Superiore Sant'Anna
Zitieren
APA
Ghionzoli, N., Gentile, F., Del Franco, A. M., Castiglione, V., Aimo, A., Giannoni, A., Burchielli, S., Cameli, M., Emdin, M., & Vergaro, G. (2022). Current and emerging drug targets in heart failure treatment. Heart Failure Reviews, 27(4), 1119-1136. https://doi.org/10.1007/s10741-021-10137-2
Vancouver
Ghionzoli N, Gentile F, Del Franco AM, Castiglione V, Aimo A, Giannoni A, et al. Current and emerging drug targets in heart failure treatment. Heart Failure Reviews. 2022;27(4):1119-1136. doi:10.1007/s10741-021-10137-2
BibTeX
@article{Ghionzoli2022,
author = {Ghionzoli, Nicolò and Gentile, Francesco and Del Franco, Anna Maria and Castiglione, Vincenzo and Aimo, Alberto and Giannoni, Alberto and Burchielli, Silvia and Cameli, Matteo and Emdin, Michele and Vergaro, Giuseppe},
title = {Current and emerging drug targets in heart failure treatment},
journal = {Heart Failure Reviews},
year = {2022},
volume = {27},
number = {4},
pages = {1119--1136},
doi = {10.1007/s10741-021-10137-2}
}
EUVIMED